Shuvam Chaudhuri

Shuvam Chaudhuri

Auto-generated profile, based on publicly available information

Shuvam Chaudhuri

Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Antiviral Research
Verified
Journal Article
Open access
SCShuvam Chaudhuri
Shuvam Chaudhuri
JSJulian A. Symons
Julian A. Symons
JDJerome Deval
Jerome Deval
2017 marked the 30th anniversary of the approval of zidovudine (AZT) as the first HIV/AIDS therapy. Since then, more than eighty antiviral drugs have received FDA approval, half of which treat HIV infection. Here, we provide a retrospective analysis of approved antiviral drugs, including therapeutics against other major chronic infections such as hepatitis B and C, and herpes viruses, over the last thirty years. During this time, only a few drugs were approved to treat acute viral infections, mainly influenza. Analysis of these approved antiviral drugs based on molecular class and mode of action shows that a large majority are small molecules and direct-acting agents as opposed to proteins, peptides, or oligonucleotides and host-targeting therapies. In addition, approvals of combination therapies accelerated over the last five years. We also provide a prospective study of future potential antiviral therapies, based on current clinical research pipelines across the pharmaceutical industry. Comparing past drug approvals with current clinical candidates hints at the future evolution in antiviral therapies and reveals how antiviral medicines are often discovered. Overall, this work helps forecast future trends and innovation in the field of antiviral research and development.

29 November 2021 in Molecular Cell
Verified
Journal Article
Closed access
JWJuncheng Wei
Juncheng Wei
BHBryan T. Harada
Bryan T. Harada
DLDan Lu
Dan Lu
RMRuihua Ma
Ruihua Ma
BGBeixue Gao
Beixue Gao
DFDeyu Fang
Deyu Fang

23 November 2022 in Science Advances
Verified
Journal Article
Open access
EMElena Montauti
Elena Montauti
SWSamuel Weinberg
Samuel Weinberg
PCPeng Chu
Peng Chu
SCShuvam Chaudhuri
Shuvam Chaudhuri
NMNikita L. Mani
Nikita L. Mani
DFDeyu Fang
Deyu Fang
The tumor microenvironment (TME) enhances regulatory T (T reg ) cell stability and immunosuppressive functions through up-regulation of lineage transcription factor Foxp3, a phenomenon known as T reg fitness or adaptation. Here, we characterize previously unknown TME-specific cellular and molecular mechanisms underlying T reg fitness. We demonstrate that TME-specific stressors including transforming growth factor–β (TGF-β), hypoxia, and nutrient deprivation selectively induce two Foxp3-specific deubiquitinases, ubiquitin-specific peptidase 22 ( Usp22 ) and Usp21 , by regulating TGF-β, HIF, and mTOR signaling, respectively, to maintain T reg fitness. Simultaneous deletion of both USPs in T reg cells largely diminishes TME-induced Foxp3 up-regulation, alters T reg metabolic signatures, impairs T reg -suppressive function, and alleviates T reg suppression on cytotoxic CD8 + T cells. Furthermore, we developed the first Usp22 -specific small-molecule inhibitor, which dramatically reduced intratumoral T reg Foxp3 expression and consequently enhanced antitumor immunity. Our findings unveil previously unappreciated mechanisms underlying T reg fitness and identify Usp22 as an antitumor therapeutic target that inhibits T reg adaptability in the TME.

1 July 2017 in Antiviral Research
Verified
Journal Article
Open access
ZJZhinan Jin
Zhinan Jin
AKApril Kinkade
April Kinkade
IBIshani Behera
Ishani Behera
SCShuvam Chaudhuri
Shuvam Chaudhuri
KTKathryn Tucker
Kathryn Tucker
JDJerome Deval
Jerome Deval
Recent cases of severe toxicity during clinical trials have been associated with antiviral ribonucleoside analogs (e.g. INX-08189 and balapiravir). Some have hypothesized that the active metabolites of toxic ribonucleoside analogs, the triphosphate forms, inadvertently target human mitochondrial RNA polymerase (POLRMT), thus inhibiting mitochondrial RNA transcription and protein synthesis. Others have proposed that the prodrug moiety released from the ribonucleoside analogs might instead cause toxicity. Here, we report the mitochondrial effects of several clinically relevant and structurally diverse ribonucleoside analogs including NITD-008, T-705 (favipiravir), R1479 (parent nucleoside of balapiravir), PSI-7851 (sofosbuvir), and INX-08189 (BMS-986094). We found that efficient substrates and chain terminators of POLRMT, such as the nucleoside triphosphate forms of R1479, NITD-008, and INX-08189, are likely to cause mitochondrial toxicity in cells, while weaker chain terminators and inhibitors of POLRMT such as T-705 ribonucleoside triphosphate do not elicit strong in vitro mitochondrial effects. Within a fixed 3'-deoxy or 2'-C-methyl ribose scaffold, changing the base moiety of nucleotides did not strongly affect their inhibition constant (Ki) against POLRMT. By swapping the nucleoside and prodrug moieties of PSI-7851 and INX-08189, we demonstrated that the cell-based toxicity of INX-08189 is mainly caused by the nucleoside component of the molecule. Taken together, these results show that diverse 2' or 4' mono-substituted ribonucleoside scaffolds cause mitochondrial toxicity. Given the unpredictable structure-activity relationship of this ribonucleoside liability, we propose a rapid and systematic in vitro screen combining cell-based and biochemical assays to identify the early potential for mitochondrial toxicity.

2 November 2021 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
YZYana Zhang
Yana Zhang
MGMing Gui
Ming Gui
YWYajun Wang
Yajun Wang
NMNikita Mani
Nikita Mani
SCShuvam Chaudhuri
Shuvam Chaudhuri
DFDeyu Fang
Deyu Fang

22 November 2016 in ACS Chemical Biology
Verified
Journal Article
Open access
PJPaul C. Jordan
Paul C. Jordan
SSSarah K. Stevens
Sarah K. Stevens
YTYuen Tam
Yuen Tam
RPRyan P. Pemberton
Ryan P. Pemberton
SCShuvam Chaudhuri
Shuvam Chaudhuri
LBLeo Beigelman
Leo Beigelman
Human respiratory syncytial virus (RSV) is a negative-sense RNA virus and a significant cause of respiratory infection in infants and the elderly. No effective vaccines or antiviral therapies are available for the treatment of RSV. ALS-8176 is a first-in-class nucleoside prodrug inhibitor of RSV replication currently under clinical evaluation. ALS-8112, the parent molecule of ALS-8176, undergoes intracellular phosphorylation, yielding the active 5′-triphosphate metabolite. The host kinases responsible for this conversion are not known. Therefore, elucidation of the ALS-8112 activation pathway is key to further understanding its conversion mechanism, particularly given its potent antiviral effects. Here, we have identified the activation pathway of ALS-8112 and show it is unlike other antiviral cytidine analogs. The first step, driven by deoxycytidine kinase (dCK), is highly efficient, while the second step limits the formation of the active 5′-triphosphate species. ALS-8112 is a 2′- and 4′-modified nucleoside analog, prompting us to investigate dCK recognition of other 2′- and 4′-modified nucleosides. Our biochemical approach along with computational modeling contributes to an enhanced structure–activity profile for dCK. These results highlight an exciting potential to optimize nucleoside analogs based on the second activation step and increased attention toward nucleoside diphosphate and triphosphate prodrugs in drug discovery.